Joint Publications with Residents

Research Mentor shown in bold. Resident(s) shown in color.
  1. Harbell JW, Morgan T, Feldstein VA, Roll GR, Posselt A, Kang SM, Feng S, Hirose R, Freise CE, Stock P. Splenic Vein Thrombosis Following Pancreas Transplantation: Identification of Factors That Support Conservative Management. Am J Transplant. 2017 Jul 14. View in PubMed
  2. Wisel SA, Gardner JM, Roll GR, Harbell J, Freise CE, Feng S, Kang SM, Hirose R, Kaufman DB, Posselt AM, Stock PG. Pancreas-After-Islet Transplantation in Nonuremic Type 1 Diabetes: A Strategy for Restoring Durable Insulin Independence. Am J Transplant. 2017 Sep; 17(9):2444-2450. View in PubMed
  3. Lee RH, Roll G, Nguyen V, Willenbring H, Tang Q, Kang SM, Stock PG. Failure to achieve normal metabolic response in non-obese diabetic mice and streptozotocin-induced diabetic mice after transplantation of primary murine hepatocytes electroporated with the human proinsulin gene (p3MTChins). Transplant Proc. 2014 Jul-Aug; 46(6):2002-6. View in PubMed
  4. Terrault NA, Carter JT, Carlson L, Roland ME, Stock PG. Outcome of patients with hepatitis B virus and human immunodeficiency virus infections referred for liver transplantation. Liver Transpl. 2006 May; 12(5):801-7. View in PubMed
  5. Carter JT, Melcher ML, Carlson LL, Roland ME, Stock PG. Thymoglobulin-associated Cd4+ T-cell depletion and infection risk in HIV-infected renal transplant recipients. Am J Transplant. 2006 Apr; 6(4):753-60. View in PubMed
  6. Fuller TF, Brennan TV, Feng S, Kang SM, Stock PG, Freise CE. End stage polycystic kidney disease: indications and timing of native nephrectomy relative to kidney transplantation. J Urol. 2005 Dec; 174(6):2284-8. View in PubMed
  7. Lipshutz GS, Mahanty H, Feng S, Hirose R, Stock PG, Kang SM, Posselt AM, Freise CE. BKV in simultaneous pancreas-kidney transplant recipients: a leading cause of renal graft loss in first 2 years post-transplant. Am J Transplant. 2005 Feb; 5(2):366-73. View in PubMed
  8. Freise CE, Kang SM, Feng S, Posselt A, Hirose K, Hirose R, Stock P. Experience with steroid-free maintenance immunosuppression in simultaneous pancreas-kidney transplantation. Transplant Proc. 2004 May; 36(4):1067-8. View in PubMed
  9. Lipshutz GS, Mahanty H, Feng S, Hirose R, Stock PG, Kang SM, Freise CE. Polyomavirus-associated nephropathy in simultaneous kidney-pancreas transplant recipients: a single-center experience. Transplant Proc. 2004 May; 36(4):1097-8. View in PubMed
  10. Freise CE, Kang SM, Feng S, Hirose R, Stock P. Excellent short-term results with steroid-free maintenance immunosuppression in low-risk simultaneous pancreas-kidney transplantation. Arch Surg. 2003 Oct; 138(10):1121-5; discussion 1125-6. View in PubMed
  11. Fuller TF, Kang SM, Hirose R, Feng S, Stock PG, Freise CE. Management of lymphoceles after renal transplantation: laparoscopic versus open drainage. J Urol. 2003 Jun; 169(6):2022-5. View in PubMed
  12. Chang GJ, Liu T, Feng S, Bedolli M, O'rourke RW, Schmidt G, Roberts JP, Stock PG. Targeted gene therapy with CD40Ig to induce long-term acceptance of liver allografts. Surgery. 2002 Aug; 132(2):149-56. View in PubMed
  13. Chang GJ, Mahanty HD, Vincenti F, Freise CE, Roberts JP, Ascher NL, Stock PG, Hirose R. A calcineurin inhibitor-sparing regimen with sirolimus, mycophenolate mofetil, and anti-CD25 mAb provides effective immunosuppression in kidney transplant recipients with delayed or impaired graft function. Clin Transplant. 2000 Dec; 14(6):550-4. View in PubMed
  14. Chang GJ, Mahanty HD, Quan D, Freise CE, Ascher NL, Roberts JP, Stock PG, Hirose R. Experience with the use of sirolimus in liver transplantation--use in patients for whom calcineurin inhibitors are contraindicated. Liver Transpl. 2000 Nov; 6(6):734-40. View in PubMed
  15. Lee CM, Carter JT, Randall HB, Hiose R, Stock PG, Melzer JS, Dafoe DC, Freise CE, Alfrey EJ. The effect of age and prolonged cold ischemia times on the national allocation of cadaveric renal allografts. J Surg Res. 2000 Jun 01; 91(1):83-8. View in PubMed
  16. Kang SM, Braat D, Schneider DB, O'Rourke RW, Lin Z, Ascher NL, Dichek DA, Baekkeskov S, Stock PG. A non-cleavable mutant of Fas ligand does not prevent neutrophilic destruction of islet transplants. Transplantation. 2000 May 15; 69(9):1813-7. View in PubMed
  17. O'Rourke RW, Kang SM, Lower JA, Feng S, Ascher NL, Baekkeskov S, Stock PG. A dendritic cell line genetically modified to express CTLA4-IG as a means to prolong islet allograft survival. Transplantation. 2000 Apr 15; 69(7):1440-6. View in PubMed
  18. O'Rourke RW, Osorio RW, Freise CE, Lou CD, Garovoy MR, Bacchetti P, Ascher NL, Melzer JS, Roberts JP, Stock PG. Flow cytometry crossmatching as a predictor of acute rejection in sensitized recipients of cadaveric renal transplants. Clin Transplant. 2000 Apr; 14(2):167-73. View in PubMed
  19. Hirose R, Roberts JP, Quan D, Osorio RW, Freise C, Ascher NL, Stock PG. Experience with daclizumab in liver transplantation: renal transplant dosing without calcineurin inhibitors is insufficient to prevent acute rejection in liver transplantation. Transplantation. 2000 Jan 27; 69(2):307-11. View in PubMed
  20. Narumi S, Osorio RW, Freise CE, Stock PG, Roberts JP, Ascher NL. Hepatic artery pseudoaneurysm with hemobilia following angioplasty after liver transplantation. Clin Transplant. 1998 Dec; 12(6):508-10. View in PubMed
  21. Kang SM, Lin Z, Ascher NL, Stock PG. Fas ligand expression on islets as well as multiple cell lines results in accelerated neutrophilic rejection. Transplant Proc. 1998 Mar; 30(2):538. View in PubMed
  22. Kang SM, Hoffmann A, Le D, Springer ML, Stock PG, Blau HM. Immune response and myoblasts that express Fas ligand. Science. 1997 Nov 14; 278(5341):1322-4. View in PubMed
  23. Kang SM, Schneider DB, Lin Z, Hanahan D, Dichek DA, Stock PG, Baekkeskov S. Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction. Nat Med. 1997 Jul; 3(7):738-43. View in PubMed
  24. Osorio RW, Ascher NL, Melzer JS, Stock PG. Enhancement of islet allograft survival in mice treated with MHC class I specific F(ab')2 alloantibody. Transplant Proc. 1994 Apr; 26(2):749. View in PubMed
  25. Osorio RW, Ascher NL, Melzer JS, Stock PG. beta-2 Microglobulin gene disruption prolongs murine islet allograft survival in NOD mice. Transplant Proc. 1994 Apr; 26(2):752. View in PubMed
  26. Osorio RW, Ascher NL, Stock PG. Prolongation of in vivo mouse islet allograft survival by modulation of MHC class I antigen. Transplantation. 1994 Mar 27; 57(6):783-8. View in PubMed
  27. Osorio RW, Ascher NL, Jaenisch R, Freise CE, Roberts JP, Stock PG. Major histocompatibility complex class I deficiency prolongs islet allograft survival. Diabetes. 1993 Oct; 42(10):1520-7. View in PubMed
  28. Osorio RW, Freise CE, Stock PG, Lake JR, Laberge JM, Gordon RL, Ring EJ, Ascher NL, Roberts JP. Nonoperative management of biliary leaks after orthotopic liver transplantation. Transplantation. 1993 May; 55(5):1074-7. View in PubMed
  29. Stock PG, Ascher NL, Osorio RW, Tomlanovich S, Lake JR, Nikolai B, Freise C, Roberts JP. Standard sequential immunosuppression with Minnesota antilymphoblast globulin and cyclosporine vs FK 506: a comparison of early nephrotoxicity. Transplant Proc. 1993 Feb; 25(1 Pt 1):675-6. View in PubMed
  30. Osorio RW, Ascher NL, Jaenisch R, Natuzzi ES, Freise CE, Roberts JP, Stock PG. Isolation of functional MHC class I-deficient islet cells. Transplant Proc. 1993 Feb; 25(1 Pt 2):968-9. View in PubMed
Data provided by UCSF Profiles, powered by CTSI at UCSF. View profile of Peter G. Stock, M.D., Ph.D.
Please note: UCSF Profiles publications are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact CTSI for help.